Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17019
Country/Region: South Africa
Year: 2017
Main Partner: Anova Health Institute
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $2,909,005 Additional Pipeline Funding: $313,527

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $937,867
Care: TB/HIV (HVTB) $69,417
Care: Pediatric Care and Support (PDCS) $0
Testing: HIV Testing and Counseling (HVCT) $105,136
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: Adult Treatment (HTXS) $1,796,585
Treatment: Pediatric Treatment (PDTX) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST By Key Population: MSM, Negative 2018 26,475
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 30,506
HTS_TST Service Delivery Point (Facility) VMMC: 50+, Negative 2018 93
HTS_TST Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative 2018 19,382
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative 2018 6,884
HTS_TST Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative 2018 56
HTS_TST Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative 2018 47
HTS_TST Sum of Test Result disaggregates 2018 4,031
HTS_TST_POS By Key Population: MSM, Positive 2018 4,031
HTS_TST_POS By Test Result: Positive 2018 4,031
HTS_TST_POS Service Delivery Point (Facility) VMMC: 50+, Positive 2018 7
HTS_TST_POS Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive 2018 3,423
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive 2018 565
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive 2018 28
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive 2018 6
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 26,022
KP_PREV By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 805
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2018 26,827
PrEP_NEW Male 15-19 2018 72
PrEP_NEW Male 20-24 2018 110
PrEP_NEW Male 25-49 2018 2,940
PrEP_NEW Male 50+ 2018 754
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2018 3,876
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 155
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 163
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 155
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 163
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 32
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 19
TB_PREV By Therapy type (Numerator): Continuous IPT 2018 4
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 32
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 65
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 65
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 39
TB_PREV_den By Therapy type (Denominator): Continuous IPT 2018 26
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 264
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 264
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 267
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 267
TX_CURR Aggregated Age/Sex: 15+ Male 2018 4,019
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 4,019
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 4,019
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 4,019
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 892
TX_NEW MSM 2018 892
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 892
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 892
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 4,823
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 3,617
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 3,617
TX_PVLS Numerator: Indication: Routine 2018 3,617
TX_PVLS Unknown Age, Routine, Male 2018 2,192
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 2,631
TX_PVLS_den Denominator: Indication: Routine 2018 3,839
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 2,265
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 2,265
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 3,020
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 3,020
Cross Cutting Budget Categories and Known Amounts Total: $3,057,890
Key Populations: MSM and TG $2,909,005
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Monitoring and evaluation of MSM/TG programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Motor Vehicles: Leased $91,385
Condoms: Commodities $57,500